Fortress Biotech (NASDAQ:FBIO) Downgraded by StockNews.com

StockNews.com lowered shares of Fortress Biotech (NASDAQ:FBIO) from a hold rating to a sell rating in a report issued on Monday morning.

Several other equities analysts have also weighed in on FBIO. Roth Mkm reissued a buy rating and issued a $10.00 price objective on shares of Fortress Biotech in a research report on Thursday, May 16th. Alliance Global Partners started coverage on shares of Fortress Biotech in a research report on Tuesday, March 19th. They issued a buy rating and a $5.00 price objective on the stock.

Fortress Biotech Stock Performance

Shares of FBIO stock opened at $1.78 on Monday. The stock has a market cap of $35.45 million, a P/E ratio of -0.29 and a beta of 1.68. The company has a debt-to-equity ratio of 38.42, a current ratio of 1.33 and a quick ratio of 1.21. The company has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $2.09. Fortress Biotech has a one year low of $1.24 and a one year high of $10.65.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.00. The firm had revenue of $13.03 million during the quarter, compared to analysts’ expectations of $14.33 million. Fortress Biotech had a negative net margin of 69.13% and a negative return on equity of 770.86%. As a group, equities analysts predict that Fortress Biotech will post -5.07 EPS for the current year.

Institutional Investors Weigh In On Fortress Biotech

Large investors have recently bought and sold shares of the company. Wealth Management Partners LLC acquired a new stake in shares of Fortress Biotech in the 4th quarter valued at approximately $60,000. Choreo LLC acquired a new stake in shares of Fortress Biotech in the 4th quarter valued at approximately $109,000. Gladstone Institutional Advisory LLC acquired a new stake in shares of Fortress Biotech in the 4th quarter valued at approximately $36,000. Armistice Capital LLC acquired a new stake in shares of Fortress Biotech in the 4th quarter valued at approximately $1,794,000. Finally, PVG Asset Management Corp acquired a new stake in shares of Fortress Biotech in the 4th quarter valued at approximately $396,000. 96.51% of the stock is currently owned by institutional investors and hedge funds.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.